These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10549391)

  • 1. New reverse transcriptase inhibitors.
    Crowe S
    Adv Exp Med Biol; 1999; 458():183-97. PubMed ID: 10549391
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
    De Clercq E
    Antiviral Res; 1998 Jun; 38(3):153-79. PubMed ID: 9754886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
    Balzarini J; De Clercq E; Carbonez A; Burt V; Kleim JP
    AIDS Res Hum Retroviruses; 2000 Apr; 16(6):517-28. PubMed ID: 10777142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1.
    Moreno S; Casado JL; Pérez-Elías MJ; Dronda F; Antela A; Moreno A; Gutiérrez C
    AIDS; 2003 Jun; 17(9):1413-4. PubMed ID: 12799573
    [No Abstract]   [Full Text] [Related]  

  • 5. Antiretrovirals, Part II: focus on non-protease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors).
    Zapor MJ; Cozza KL; Wynn GH; Wortmann GW; Armstrong SC
    Psychosomatics; 2004; 45(6):524-35. PubMed ID: 15546830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rilpivirine: a step forward in tailored HIV treatment.
    Schrijvers R; Desimmie BA; Debyser Z
    Lancet; 2011 Jul; 378(9787):201-3. PubMed ID: 21763920
    [No Abstract]   [Full Text] [Related]  

  • 7. What they say about: non-nucleoside drugs.
    Posit Aware; 2000; 11(1):44-7. PubMed ID: 11366350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of current NNRTIs and perspectives of new agents in this class under development.
    Zhang Z; Hamatake R; Hong Z
    Antivir Chem Chemother; 2004 May; 15(3):121-34. PubMed ID: 15266894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for second-line antiretroviral therapy in adults with HIV infection.
    Collier AC; Schwartz MA
    Adv Exp Med Biol; 1999; 458():239-66. PubMed ID: 10549396
    [No Abstract]   [Full Text] [Related]  

  • 10. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three new drugs for HIV infection.
    Med Lett Drugs Ther; 1998 Dec; 40(1041):114-6. PubMed ID: 9854567
    [No Abstract]   [Full Text] [Related]  

  • 12. Protease inhibitor-sparing regimens: new evidence strengthens position.
    Moyle GJ
    J Acquir Immune Defic Syndr; 2003 Jun; 33 Suppl 1():S17-25; quiz S26-8. PubMed ID: 12946062
    [No Abstract]   [Full Text] [Related]  

  • 13. [3 years' data of tenofovir. Confirmed as a valuable building block].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():30-1. PubMed ID: 15373042
    [No Abstract]   [Full Text] [Related]  

  • 14. Elvucitabine data released at CROI.
    AIDS Patient Care STDS; 2010 Mar; 24(3):198. PubMed ID: 20235383
    [No Abstract]   [Full Text] [Related]  

  • 15. [Progress in HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs)].
    Zhou T; Xie L
    Yao Xue Xue Bao; 2004 Aug; 39(8):666-72. PubMed ID: 15563074
    [No Abstract]   [Full Text] [Related]  

  • 16. International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance.
    Deeks SG
    J Acquir Immune Defic Syndr; 2001 Mar; 26 Suppl 1():S25-33. PubMed ID: 11264999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo dynamics of the 103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in HIV-infected patients: preliminary results.
    Gianotti N; Boeri E; Maillard M; Serra G; Ratti D; Gallotta G; Vacchini D; Tremolada Y; Castagna A
    New Microbiol; 2004 Apr; 27(2 Suppl 1):111-7. PubMed ID: 15646073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New expanded access drugs for use in combination therapy.
    Notes Undergr; 1998; (No 37):suppl 1-2. PubMed ID: 11365823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
    Bayonne Kombo ES; Gathse A
    Med Mal Infect; 2013 Mar; 43(3):134-5. PubMed ID: 23434355
    [No Abstract]   [Full Text] [Related]  

  • 20. NNRTIs: a neglected class.
    Cadman J
    GMHC Treat Issues; 1998 Sep; 12(9):6-10. PubMed ID: 11365807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.